1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
The clinical characteristics of 77 patients who presented with acute transverse myelitis
CharacteristicsMonophasic (n = 50)Recurrent (n = 27)P Values
Age at initial manifestation (mean) (yr)34.2 ± 20.640.4 ± 18.5.196
Female (n) (%)25 (50%)21 (77.8%).033
Ethnicity.020
    African American (n) (%)10 (20%)10 (37%)
    Caucasian (n) (%)38 (76%)12 (44.4%)
    Asian American (n) (%)1 (2%)3 (11%)
    Hispanic (n) (%)1 (2%)2 (7.4%)
Seropositivity for anti-AQP4 Ab1 (2%)8 (29.6%).003
Mean follow-up time (yr)2.4 ± 1.73.8 ± 3.8.023
Mean EDSS score4.2 ± 2.13.3 ± 1.8.064
Patients with follow-up spine MRIs (n) (%)16 (32%)27 (100%)<.001
Use of immunosuppressive/immunomodulatory treatment (n) (%)9 (18%)18 (66.7%)<.001
  • Note:—AQP4 Ab indicates aquaporin 4 antibody.